Showing 5151-5160 of 5644 results for "".
- Canon USA to Showcase Eyecare Solutions At AAOhttps://modernod.com/news/canon-usa-to-showcase-eyecare-solutions-at-aao/2476971/Canon U.S.A. will be showcasing the recently FDA 510(k) cleared Xephilio OCT-A1 Optical Coherence Tomography device, together with the required RX Capture software, computer and LCD monitor,collectively, the “Xephilio OCT-A1 System, at the American Academy o
- QuickSee Handheld Autorefractor Shows Strong Agreement With Subjective Refraction Measurementshttps://modernod.com/news/quicksee-handheld-autorefractor-shows-strong-agreement-with-subjective-refraction-measurements/2476968/PlenOptika, maker of the QuickSee handheld autorefractor, announced the publication of research showing their device produces measurements in strong agreement with subjective refraction and traditional autorefraction technology. The paper “<
- AAO and Verana Health Accelerate Clinical Trials for Patients with Rare, Sight-Threatening Retinal Diseases Through Verana Trial Connecthttps://modernod.com/news/aao-and-verana-health-accelerate-clinical-trials-for-patients-with-rare-sight-threatening-retinal-diseases-through-verana-trial-connect/2476962/The American Academy of Ophthalmology (AAO) and Verana Health announced that they are now facilitating no-cost genetic testing and counseling for patients with certain inherited retinal diseases through Verana Trial Connect, a powerful cloud-based application that facilitates physician and patien
- Orbis International Calls for “All Eyes on 2020” and Preserving the Future of Visionhttps://modernod.com/news/orbis-international-calls-for-all-eyes-on-2020-and-preserving-the-future-of-vision/2476963/On the eve of World Sight Day, Orbis International is celebrating achievements of the eye health community over the past two decades, and warns of a projected global tripling in demand for eye care over the next 30 years. 2020 is a critical year for Orbis International and other leaders in
- GenSight Biologics Reports Evidence of GS010 DNA Transfer to Contralateral Eye of Primates Unilaterally Injected With GS010 Gene Therapyhttps://modernod.com/news/gensight-biologics-reports-evidence-of-gs010-dna-transfer-to-contralateral-eye-of-primates-unilaterally-injected-with-gs010-gene-therapy/2476960/GenSight Biologics reported positive proof of GS010 DNA transfer from one eye to the other eye following unilateral intravitreal injection of primates. In a nonclinical study to investigate the local biodistribution of GS010, tissue samples from the non-injected eye of monkeys that had been unila
- LensGen to Review Latest Juvene IOL Results At AAOhttps://modernod.com/news/lensgen-to-review-latest-juvene-iol-results-at-aao/2476954/LensGen will review its latest data for the world’s first modular fluid optic IOL in several activities around the American Academy of Ophthalmology (AAO) annual meeting in San Francisco this week. LensGen developed Juvene, which uses biomimetic design princ
- Johnson & Johnson Vision Launches Worldwide #ConnectedBySight Campaign in Honor of World Sight Dayhttps://modernod.com/news/johnson-johnson-vision-launches-worldwide-connectedbysight-campaign-in-honor-of-world-sight-day/2476949/In honor of World Sight Day on October 10, 2019, Johnson & Johnson Vision has launched a worldwide campaign to share the untold stories of eye care professionals, patients, and organizations who are inspiring the elevation of eye health as a global priority and demonstrating how the world is
- Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-dosing-of-first-patient-in-randomized-phase-2b-skyggn-clinical-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2476947/Oculis announced the dosing of the first patient in a phase 2b clinical trial evaluating the efficacy and safety of OCS-01 for the treatment of inflammation and pain following cataract surgery. OCS-01 is a unique topical formulation of dexamethasone based on the company’s proprietary
- TECLens and SERVImed Industrial Spa Announce Partnership to Pursue FDA Approval for Transepithelial Corneal Cross-Linkinghttps://modernod.com/news/teclens-and-servimed-industrial-spa-announce-partnership-to-pursue-fda-approval-for-trans-epithelial-corneal-cross-linking/2476941/Medical device manufacturer TECLens announced a partnership with Italian medical device maker SERVimed Industrial Spa aimed at the development and FDA approval of a new combination product to treat keratoconus. The ne
- Vision 2020 USA to Hold Annual World Sight Day Briefing on October 17, 2019https://modernod.com/news/vision-2020-usa-to-hold-annual-world-sight-day-briefing-on-october-17-2019/2476939/As part of World Sight Day events, on Oct. 17, 2019, Vision 2020 USA will be holding an educational luncheon briefing at the Rayburn House Office Building, 2075, in aWashington DC, from noon to 1 p.m. According to Prevent Blindness, by 2050, the impaired and blind populations are projecte